A STUDY OF ENFORTUMAB VEDOTIN (ASG-22CE) AS MONOTHERAPY OR IN COMBINATION WITH ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER

Registry ID

SGN22E-002

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

SEAGEN INC.

Start date

2021-07-27

Last update

2020-09-15

Conditions

• UROTHELIAL CANCER

Related clinical trials

• A PHASE III, OPEN-LABEL, RANDOMISED, MULTICENTRE, GLOBAL STUDY OF ADJUVANT DATOPOTAMAB DERUXTECAN IN COMBINATION WITH RILVEGOSTOMIG IN PARTICIPANTS WITH HIGH-RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA (TROPION-UROTHELIAL04)
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF SACITUZUMAB TIRUMOTECAN (MK-2870) CARCINOMA VERSUS INVESTIGATOR’S CHOICE OF NON-PLATINUM CHEMOTHERAPY IN PARTICIPANTS WITH PRETREATED LOCALLY ADVANCED/METASTATIC UROTHELIAL
• IZABRIGHT-BLADDER01: A RANDOMIZED, OPEN-LABEL, PHASE 2/3 TRIAL OF IZALONTAMAB BRENGITECAN VERSUS PLATINUM-BASED CHEMOTHERAPY FOR METASTATIC UROTHELIAL CANCER IN PARTICIPANTS WITH DISEASE PROGRESSION ON OR AFTER AN IMMUNOTHERAPY-BASED TREATMENT
• A PHASE 1/2, SINGLE-ARM, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF NADOFARAGENE FIRADENOVEC INSTILLED TO THE RENAL PELVIS IN ADULT SUBJECTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA (LG-UTUC)
• MODERN: AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRDBASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL CANCER
• A RANDOMIZED OPEN-LABEL PHASE 2/3 STUDY OF BT8009 AS MONOTHERAPY OR IN COMBINATION IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (DURAVELO-2)

View on source registry